News
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
3h
Zacks.com on MSNFDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger AdultsFDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.
Pharmalittle: We’re reading about Regeneron’s patent maneuvers, FDA rejection letters, and lots more
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results